Authors:
Zeana, C
Kubin, CJ
Della-Latta, P
Hammer, SM
Citation: C. Zeana et al., Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: Case report and review of the literature, CLIN INF D, 33(4), 2001, pp. 477-482
Authors:
Staszewski, S
Keiser, P
Montaner, J
Raffi, F
Gathe, J
Brotas, V
Hicks, C
Hammer, SM
Cooper, D
Johnson, M
Tortell, S
Cutrell, A
Thorborn, D
Isaacs, R
Hetherington, S
Steel, H
Spreen, W
Citation: S. Staszewski et al., Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults - A randomized equivalence trial, J AM MED A, 285(9), 2001, pp. 1155-1163
Authors:
Albrecht, MA
Bosch, RJ
Hammer, SM
Liou, SH
Kessler, H
Para, MF
Eron, J
Valdez, H
Dehlinger, M
Katzenstein, DA
Citation: Ma. Albrecht et al., Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection., N ENG J MED, 345(6), 2001, pp. 398-407
Authors:
Lathey, JL
Tierney, C
Chang, SYP
D'Aquila, RT
Bettendorf, DM
Alexander, HC
Santini, CD
Hughes, AM
Barroga, CF
Spector, SA
Landes, JE
Hammer, SM
Katzenstein, DA
Citation: Jl. Lathey et al., Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy, J INFEC DIS, 184(11), 2001, pp. 1402-1411
Authors:
Demeter, LM
Hughes, MD
Coombs, RW
Jackson, JB
Grimes, JM
Bosch, RJ
Fiscus, SA
Spector, SA
Squires, KE
Fischl, MA
Hammer, SM
Citation: Lm. Demeter et al., Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320, ANN INT MED, 135(11), 2001, pp. 954-964
Citation: Cm. Hogan et Sm. Hammer, Host determinants in HIV infection and disease part 1: Cellular and humoral immune responses, ANN INT MED, 134(9), 2001, pp. 761-776
Citation: Cm. Hogan et Sm. Hammer, Host determinants in HIV infection and disease - Part 2: Genetic factors and implications for antiretroviral therapeutics, ANN INT MED, 134(10), 2001, pp. 978-996
Authors:
Currier, JS
Spino, C
Grimes, J
Wofsy, CB
Katzenstein, DA
Hughes, MD
Hammer, SM
Cotton, DJ
Citation: Js. Currier et al., Differences between women and men in adverse events and CD4(+) responses to nucleoside analogue therapy for HIV infection, J ACQ IMM D, 24(4), 2000, pp. 316-324
Authors:
Kim, S
Hughes, MD
Hammer, SM
Jackson, JB
DeGruttola, V
Katzenstein, DA
Citation: S. Kim et al., Both serum HIV type 1 RNA levels and CD4(+) lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4(+) cells per cubic millimeter, AIDS RES H, 16(7), 2000, pp. 645-653
Authors:
Albrecht, MA
Hughes, MD
Liou, SH
Katzenstein, DA
Murphy, R
Balfour, HH
Para, MF
Valdez, H
Hammer, SM
Citation: Ma. Albrecht et al., Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine, AIDS RES H, 16(14), 2000, pp. 1337-1344
Authors:
Coakley, EPG
Samore, MH
Gillis, JM
Hughes, MD
Hammer, SM
Citation: Epg. Coakley et al., The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of <= 50 x 10(6) cells/l, AIDS, 14(9), 2000, pp. 1147-1153
Citation: Ep. Coakley et al., Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine, AIDS, 14(2), 2000, pp. F9-F15
Authors:
Carpenter, CCJ
Cooper, DA
Fischl, MA
Gatell, JM
Gazzard, BG
Hammer, SM
Hirsch, MS
Jacobsen, DM
Katzenstein, DA
Montaner, JSG
Richman, DD
Saag, MS
Schechter, M
Schooley, RT
Vella, S
Yeni, PG
Volberding, PA
Citation: Ccj. Carpenter et al., Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel, J AM MED A, 283(3), 2000, pp. 381-390
Authors:
Hirsch, MS
Brun-Vezinet, F
D'Aquila, RT
Hammer, SM
Johnson, VA
Kuritzkes, DR
Loveday, C
Mellors, JW
Clotet, B
Conway, B
Demeter, LM
Vella, S
Jacobsen, DM
Richman, DD
Citation: Ms. Hirsch et al., Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel, J AM MED A, 283(18), 2000, pp. 2417-2426
Authors:
Phanuphak, P
Grayson, ML
Sirivichayakul, S
Suwanagool, S
Ruxrungtham, K
Hanvanich, M
Ratanasuwan, W
Ubolyam, S
Hughes, MD
Wanke, CA
Hammer, SM
Citation: P. Phanuphak et al., A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection - Conducting clinical HIV trials in South-East Asia, AUST NZ J M, 30(1), 2000, pp. 11-20
Authors:
Brambilla, D
Reichelderfer, PS
Bremer, JW
Shapiro, DE
Hershow, RC
Katzenstein, DA
Hammer, SM
Jackson, B
Collier, AC
Sperling, RS
Fowler, MG
Coombs, RW
Citation: D. Brambilla et al., The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements, AIDS, 13(16), 1999, pp. 2269-2279
Citation: M. Bier et al., Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells, BIOELECTROM, 20(3), 1999, pp. 194-201
Authors:
Wanke, CA
Cohan, D
Thummakul, T
Jongwuitiwes, S
Grayson, ML
Hammer, SM
Hanvanich, M
Citation: Ca. Wanke et al., Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand, AM J TROP M, 60(5), 1999, pp. 871-874
Authors:
Simpson, DM
Katzenstein, DA
Hughes, MD
Hammer, SM
Williamson, DL
Jiang, Q
Pi, JT
Citation: Dm. Simpson et al., Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial, AIDS, 12(18), 1998, pp. 2425-2432